Diabetes Ulcers Can Now Heal Faster – A New Product is Now Seeking Regulatory Support by Potential Distributors

By Dr. Sharon Gotteiner, CPA

Dr. Sharon Gotteiner is a Certified Public Accountant (CPA) specializing in the assessment of the financial feasibility of new business ventures, business models, and deal structures. Dr. Gotteiner has extensive experience working with technology startups and established corporations worldwide, catalyzing strategic initiatives aimed at improving financial performance and enterprise valuation. Academic background: PhD in Strategic Management (UIC, Barcelona, Spain). Co-author of highly cited academic publications, including Fighting organizational decline: a risk-based approach to organizational anti-aging, Turnaround types, stages, strategies, and tactics: Putting things in order, and The OPTIMAL MBO: A model for effective management-by-objectives implementation.

Diabetic ulcers are challenging to heal and often lead to hospitalization, limb amputation, and disability. Effective wound healing begins with the crucial first step: debridement, which removes necrotic and infected tissue that hinders recovery.

Several debridement methods are commonly used; however, they are often incomplete, fail to promote healing, and present the following additional challenges:

• Surgical debridement requires specialized skills, is time-consuming, and may necessitate anesthesia.
• Enzymatic debridement is occasionally used after surgery but can cause irritation or allergic reactions.
• Autolytic debridement is a slow process and may not be suitable for infected or heavily necrotic wounds.
• Mechanical debridement, such as wet-to-dry dressings, can adhere to healthy tissue, potentially causing additional pain, trauma, and an increased risk of infection when removed.
• Antibiotics often lead to the emergence of drug-resistant bacteria load.
• Antiseptics may cause irritation, pain, allergic reactions, and may be cytotoxic to healthy cells.

An innovative, antiseptic, non-toxic irrigation product has recently been proven to deliver effective and rapid debridement, overcoming the challenges associated with current methods:

• Debridement Activity: The product penetrates and lifts biofilms and dead tissue, revealing healthy epithelium, which supports tissue regeneration.
• No Drug Resistance: This product does not contribute to the emergence of drug-resistant bacteria.
• Constant Irrigation: The product provides continuous irrigation of the wound by spraying the solution onto the bandage or dressing, helping to maintain a moist environment. This process keeps the lesion sanitized, actively debrides the wound, and promotes the development of healthy granulation tissue. The moisture also aids the body’s enzymes, neutrophils, growth factors, and macrophages in digesting and liquefying the necrotic tissue.
• Tissue Compatibility: The solution obtained from dissolving the product contains 1000 ppm (parts per million) of Latent Available Chlorine and has a pH range of 5 to 6.2. This pH level is neutral for healthy tissue, meaning it does not cause irritation, pain, or damage to new granulation tissue or other healthy cells.
• Versatility: The product can be used for all types of wounds, including diabetic ulcers, pressure sores, infected wounds, and other injuries. It promotes rapid wound healing and closure.
• Hygiene: The product’s high cleansing effectiveness has been shown to significantly reduce wound contamination.
• Ease of Use: Designed for home use, this product is easy to apply. Simply dissolve it in water and spray it onto the bandage or dressing throughout the day.

The product is already registered and is widely used by HMOs in one region. The company is now seeking collaboration with distributors to support further clinical trials, regulatory processes, and the expansion of distribution into new regions.